Volume 12, Issue 1 (2012)

This special inaugural relaunch issue of Cancer Immunity is dedicated to the memory of Dr. Lloyd Old, the journal’s founding editor-in-chief. The issue features a collection of personal reflections by some of Dr. Old’s closest collaborators, who share their narratives on him and his work at different key periods throughout his scientific career. Also included in the issue will be a set of scientific commentaries on the topic of antibodies in cancer treatment, one of the most active and exciting areas of cancer immunology research today.


Editor’s View

Pramod K. Srivastava, Vincenzo Cerundolo, Alexander Knuth, and James P. Allison
An open invitation to the cancer immunology community
Cancer Immunity (1 May 2012) Vol. 12, p. 1
Full text · PDF


Reflections

Toshitada Takahashi and Hiroshi Shiku
Cell surface antigens: invaluable landmarks reflecting the nature of cells
Cancer Immunity (1 May 2012) Vol. 12, p. 2
Full text · PDF

Hiroshi Shiku and Toshitada Takahashi
Autologous typing: a tedious, but orthodox approach for defining human tumor antigens in clarity
Cancer Immunity (1 May 2012) Vol. 12, p. 3
Full text · PDF

Elizabeth A. Richards-Carswell and Barbara D. Williamson
A man of vision and the discovery of tumor necrosis factor
Cancer Immunity (1 May 2012) Vol. 12, p. 4
Full text · PDF

Pramod K. Srivastava
Identification of chaperones as essential components of the tumor rejection moieties of cancer
Cancer Immunity (1 May 2012) Vol. 12, p. 5
Full text · PDF

Elke Jäger and Alexander Knuth
The discovery of Cancer/Testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines
Cancer Immunity (1 May 2012) Vol. 12, p. 6
Full text · PDF

Michael Pfreundschuh
The genealogy of SEREX
Cancer Immunity (1 May 2012) Vol. 12, p. 7
Full text · PDF

Yao-Tseng Chen
The journey from autologus typing to SEREX, NY-ESO-1, and Cancer/Testis antigens
Cancer Immunity (1 May 2012) Vol. 12, p. 8
Full text · PDF

Gerd Ritter
“But Dr. Old, we already have an antibody!” Reflections on Lloyd Old’s “academic biotech” approach for targeted antibodies
Cancer Immunity (1 May 2012) Vol. 12, p. 9
Full text · PDF

Jill O’Donnell-Tormey and Edward A. McDermott Jr.
The Cancer Vaccine Collaborative: a new model of coordinated clinical discovery
Cancer Immunity (1 May 2012) Vol. 12, p. 10
Full text · PDF


Commentaries

Jean-Pierre Mach
Introduction to monoclonal antibodies
Cancer Immunity (1 May 2012) Vol. 12, p. 11
Full text · PDF

Gert Riethmüller
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on
Cancer Immunity (1 May 2012) Vol. 12, p. 12
Full text · PDF

Falk Nimmerjahn and Jeffrey V. Ravetch
Translating basic mechanisms of IgG effector activity into next generation cancer therapies
Cancer Immunity (1 May 2012) Vol. 12, p. 13
Full text · PDF

Andrew M. Scott, James P. Allison, and Jedd D. Wolchok
Monoclonal antibodies in cancer therapy
Cancer Immunity (1 May 2012) Vol. 12, p. 14
Full text
· PDF